National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Clinical Trials (PDQ®)
Patient VersionHealth Professional Version
Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Clinical Trial Questions?

Get Help:

1-800-4-CANCER or

LiveHelp online chat

Quick Links
Help Using the NCI Clinical Trials Search Form

Educational Materials About Clinical Trials

About NCI's Cancer Clinical Trials Registry

Dictionary of Cancer Terms

NCI Drug Dictionary
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIISupportive careClosed18 and overNCI, OtherCDR0000333213
UCLA-0306021, AMGEN-20030125, NCT00070382

Trial Description

Summary

RATIONALE: Darbepoetin alfa and epoetin alfa may stimulate red blood cell production and treat anemia in patients who are receiving chemotherapy. It is not yet known whether darbepoetin alfa is more effective than epoetin alfa in treating patients with anemia.

PURPOSE: Randomized phase III trial to compare the effectiveness of darbepoetin alfa with that of epoetin alfa in treating anemia in patients who are receiving chemotherapy for cancer.

Further Study Information

OBJECTIVES:

Primary

  • Compare the efficacy of darbepoetin alfa vs epoetin alfa for anemia in patients with non-myeloid malignancies receiving chemotherapy.

Secondary

  • Compare the safety of these drugs in these patients.

OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified according to screening hemoglobin concentration (less than 10.0 g/dL vs 10.0-11.0 g/dL) and type of concurrent chemotherapy (platinum-based vs non-platinum-based). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive darbepoetin alfa subcutaneously (SC) every other week for 12 weeks (i.e., on weeks 1, 3, 5, 7, 9, and 11).
  • Arm II: Patients receive epoetin alfa SC once weekly for 12 weeks. Patients are followed at 1 and 3 weeks .

PROJECTED ACCRUAL: A total of 600 patients (300 per treatment arm) will be accrued for this study within 6 months.

Eligibility Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of a non-myeloid malignancy
  • The following diagnoses are excluded:
  • Acute myeloid leukemia
  • Chronic myeloid leukemia
  • Acute lymphoblastic leukemia
  • Hairy cell leukemia
  • Burkitt's lymphoma
  • Lymphoblastic lymphoma
  • Currently receiving or planning to receive at least 8 weeks of cyclic cytotoxic chemotherapy
  • Hemoglobin no greater than 11.0 g/dL
  • No other primary hematologic disorder that would cause anemia (e.g., sickle cell anemia)

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified

Hematopoietic

  • See Disease Characteristics

Hepatic

  • Bilirubin less than 2 times upper limit of normal (ULN)

Renal

  • Creatinine less than 2 times ULN

Cardiovascular

  • No angina
  • No congestive heart failure
  • No New York Heart Association class III or IV heart disease
  • No hypertension
  • No cardiac arrhythmia
  • No other unstable or uncontrolled disease or condition that would affect cardiac function

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • No known seizure disorder
  • No known sensitivity to study agents
  • No clinically significant inflammatory disease (e.g., rheumatoid arthritis or Crohn's disease)
  • No confirmed neutralizing antibodies to epoetin alfa
  • No other disorder that would preclude study compliance or giving informed consent

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • More than 30 days since prior darbepoetin alfa or epoetin alfa
  • No other concurrent epoetin alfas

Chemotherapy

  • See Disease Characteristics

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • Not specified

Other

  • More than 30 days since prior participation in investigational device or drug trials
  • No prior randomization to this study
  • No other concurrent investigational agents or procedures

Trial Contact Information

Trial Lead Organizations/Sponsors

Jonsson Comprehensive Cancer Center at UCLA

National Cancer Institute

John A. GlaspyPrincipal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00070382
Information obtained from ClinicalTrials.gov on October 19, 2009

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov